Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 13/20 | 0.63 |
| ▸ | LHCGR | P22888 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957047 | 0.85 | TRPM8 (0.62) | TRPM8 | |
| SCHEMBL4062654 | 0.84 | TRPM8 (0.66) | TRPM8 | |
| SCHEMBL3073178 | 0.83 | TRPM8 (0.67) | TRPM8 | |
| SCHEMBL4054683 | 0.77 | TRPM8 (1.00) | TRPM8LHCGROPRK1TMEM97SIGMAR1 | |
| SCHEMBL4067195 | 0.77 | TRPM8 (1.00) | TRPM8LHCGROPRK1TMEM97SIGMAR1 | |
| SCHEMBL4061392 | 0.74 | TRPM8 (0.39) | TRPM8 | |
| SCHEMBL7209587 | 0.73 | TRPM8 (0.53) | TRPM8KCNH2 | |
| SCHEMBL4067787 | 0.72 | TRPM8 (0.58) | TRPM8LHCGROPRK1TMEM97SIGMAR1 | |
| SCHEMBL22784241 | 0.70 | CHRM3 (0.62) | TRPM8KCNH2 | |
| SCHEMBL7209238 | 0.70 | CHRM3 (0.62) | TRPM8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | TRPM8 33/4885LHCGR 1595/4885OPRK1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.